8-K filed April 1, 2025, 7:59 PM ET ticker CLYM CIK 0001768446

leadership confidence high sentiment neutral materiality 0.40

Climb Bio announces board changes: two directors depart, two new directors elected

Climb Bio, Inc.

Simon Tate resigned as director on March 27, 2025, also leaving audit and nominating committees; no disagreement.
Adam Rosenberg will not seek re-election at 2025 annual meeting; no disagreement with company.
Board expanded from 7 to 8; Alexander (Bo) Cumbo and Kimberlee Drapkin elected effective March 28, 2025.
Cumbo to chair compensation committee; Drapkin to chair audit committee.
Each new director received option to purchase 80,000 shares at $1.28/share, vesting over three years.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Simon Tate

member of the board of directors

CLYM · Climb Bio, Inc.

Effective: 2025-03-27
Filed: April 1, 2025, 7:59 PM ET

Simon Tate notified Climb Bio, Inc. (the “Company”) of his decision to resign as a member of the Company’s board of directors

Appointed

Alexander (Bo) Cumbo

member of the board of directors

CLYM · Climb Bio, Inc.

Effective: 2025-03-28
Filed: April 1, 2025, 7:59 PM ET

Mr. Cumbo was elected to serve with a term expiring at the Company’s 2026 annual meeting of stockholders and thereafter until his successor has been duly appointed and qualified or until his earlier death, resignation or removal.

Appointed

Kimberlee (Kim) Drapkin

member of the board of directors

CLYM · Climb Bio, Inc.

Effective: 2025-03-28
Filed: April 1, 2025, 7:59 PM ET

Ms. Drapkin was elected to serve with a term expiring at the Company’s 2027 annual meeting of stockholders and thereafter until her successor has been duly appointed and qualified or until her earlier death, resignation or removal.

Departed

Adam Rosenberg

member of the board of directors

CLYM · Climb Bio, Inc.

Filed: April 1, 2025, 7:59 PM ET

Adam Rosenberg notified the Company that he does not intend to seek re-election as a member of the Board when his current term ends at the Company’s 2025 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Simon Tate resigned as member of the board of directors at Climb Bio, Inc..

Action: resigned
Role: member of the board of directors

Exact text from the filing

Simon Tate notified Climb Bio, Inc. (the “Company”) of his decision to resign as a member of the Company’s board of directors

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Alexander (Bo) Cumbo was elected as member of the board of directors at Climb Bio, Inc..

Action: elected
Role: member of the board of directors

Exact text from the filing

Mr. Cumbo was elected to serve with a term expiring at the Company’s 2026 annual meeting of stockholders and thereafter until his successor has been duly appointed and qualified or until his earlier death, resignation or removal.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Kimberlee (Kim) Drapkin was elected as member of the board of directors at Climb Bio, Inc..

Action: elected
Role: member of the board of directors

Exact text from the filing

Ms. Drapkin was elected to serve with a term expiring at the Company’s 2027 annual meeting of stockholders and thereafter until her successor has been duly appointed and qualified or until her earlier death, resignation or removal.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Adam Rosenberg departed as member of the board of directors at Climb Bio, Inc..

Action: does not intend to seek re-election
Role: member of the board of directors

Exact text from the filing

Adam Rosenberg notified the Company that he does not intend to seek re-election as a member of the Board when his current term ends at the Company’s 2025 annual meeting of stockholders.

View on SEC.gov

Climb Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-069668

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.